奥浦迈(688293) - 投资者关系活动记录表

Group 1: Company Performance - In the first half of 2024, the company achieved operating revenue of 144 million CNY, an increase of 18.44% compared to the same period last year [6] - The net profit attributable to shareholders was 24.14 million CNY, a decrease of 36.29% year-on-year [6] - The total assets reached 2.271 billion CNY, reflecting a slight decrease of 1.37% due to dividend distribution [6] Group 2: Business Growth and Client Pipeline - As of June 30, 2024, the company had 216 confirmed drug development pipelines using its cell culture products, an increase of 46 pipelines (27.06%) compared to the end of 2023 [4] - The company has served over 1,400 domestic and international biopharmaceutical enterprises and research institutions [7] - The CDMO business assisted clients in obtaining 5 clinical approvals and one project received NMPA market approval [4] Group 3: Product Development and Innovation - The company developed 15 customized CHO cell culture products, with over half used in pilot scale projects [5] - The company’s CDMO platform has completed construction and entered trial production, enhancing service capabilities [5] - The company’s R&D investment totaled approximately 15.38 million CNY, accounting for 10.71% of operating revenue, although it decreased by 25.71% year-on-year [6] Group 4: Financial Metrics and Challenges - The company reported a gross profit margin decline due to structural impacts from its two main business segments [9] - Operating costs increased primarily due to rising revenue and expenses related to the CDMO platform [6] - The overseas revenue reached 45.20 million CNY, a significant increase of 226.58% compared to the previous year [6] Group 5: Strategic Adjustments and Future Outlook - The company plans to increase mid-term cash dividends to 2.20 CNY per 10 shares, reflecting a commitment to investor returns [7] - Adjustments to the stock incentive plan were made to align performance targets with current market conditions and company strategy [8] - The company aims to enhance operational efficiency and strengthen internal management to prepare for future growth [7]